Mounjaro vs Ozempic: compare tirzepatide and semaglutide on weight loss, A1C results, dosing, cost, and side effects in this plain-English guide.
Mounjaro (tirzepatide) and Ozempic (semaglutide) are both once-weekly injectable medications that lower blood sugar and often cause weight loss, but they are not the same drug. Mounjaro targets two hormone receptors, GIP and GLP-1, while Ozempic targets only GLP-1. That mechanistic difference helps explain why the two medications produce different average results for A1C and body weight.
What Are Mounjaro and Ozempic?
Mounjaro is the Eli Lilly brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist. The FDA approved Mounjaro in 2022 for adults with type 2 diabetes. The identical molecule is sold as Zepbound for chronic weight management.
Ozempic is the Novo Nordisk brand name for semaglutide, a GLP-1 receptor agonist approved in 2017 for type 2 diabetes. A higher-dose version of semaglutide is sold as Wegovy for weight loss.
Confusion between brand names and generic names is common. Mounjaro is the brand name for tirzepatide, so tirzepatide vs mounjaro is really a brand-versus-ingredient comparison, not a choice between two separate drugs.
Mounjaro vs Ozempic at a Glance
| Feature | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| FDA-approved for | Type 2 diabetes (weight loss under Zepbound) | Type 2 diabetes (weight loss under Wegovy) |
| Starting dose | 2.5 mg weekly | 0.25 mg weekly |
| Maximum weekly dose | 15 mg | 2 mg |
| Average A1C reduction | About 2.0-2.3% | About 1.4-1.9% |
| Average weight loss | Up to 22.5% (SURMOUNT-1, 15 mg) | About 14.9% (STEP-1, 2.4 mg) |
| Common side effects | Nausea, diarrhea, vomiting, constipation | Nausea, vomiting, diarrhea, constipation |
| List price (no insurance) | About $1,000-$1,100 per month | About $1,000 per month |
A1C and Blood Sugar Results
In the SURPASS-2 trial, researchers compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes. Tirzepatide produced larger A1C reductions at every dose studied.
Ozempic remains highly effective on its own. Many people reach their A1C target on semaglutide and tolerate it well, which matters because tolerability often determines whether someone stays on a medication long term.
Key conclusion: In the SURPASS-2 trial, tirzepatide lowered A1C more than semaglutide 1 mg, but both drugs produced clinically meaningful improvements in blood sugar control.
Weight Loss: Tirzepatide vs Semaglutide
No large trial has directly compared Mounjaro and Ozempic at their weight-loss doses. Instead, doctors rely on separate trials of the same molecules at higher doses.
- SURMOUNT-1: tirzepatide 15 mg produced average weight loss of about 22.5% over 72 weeks in adults without diabetes.
- STEP-1: semaglutide 2.4 mg produced average weight loss of about 14.9% over 68 weeks in a similar population.
Cross-trial comparisons are imperfect because study populations, doses, and time frames differ. Even so, the pattern is consistent across multiple analyses.
People who search tirzepatide vs mounjaro for weight loss are usually trying to sort out the difference between Zepbound and Mounjaro, which contain the same active ingredient. Shorthand like sema vs tirz or tirz vs sema refers to the same semaglutide-versus-tirzepatide question.
Key conclusion: Averaged across clinical trials, tirzepatide produces greater weight loss than semaglutide, but individual results vary widely.
Side Effects and Safety Considerations
Both drugs share a similar side-effect profile because they act on the GLP-1 pathway. Most problems are gastrointestinal and ease after the first few weeks of each dose increase.
- Common: nausea, vomiting, diarrhea, constipation, stomach pain, fatigue.
- Less common: pancreatitis, gallbladder disease, kidney injury from dehydration, worsening diabetic retinopathy.
- Boxed warning: thyroid C-cell tumors seen in rodents; not recommended for people with a personal or family history of medullary thyroid cancer or MEN2.
Neither medication is approved for use during pregnancy, and both should be stopped before attempting conception. Anyone with a history of pancreatitis or severe gastroparesis should discuss risks with a clinician first.
Key conclusion: Mounjaro and Ozempic both carry a boxed warning for thyroid C-cell tumors and should not be used during pregnancy.
Cost, Insurance, and Availability
List prices for both brands sit near or above $1,000 per month without insurance. Actual out-of-pocket spending depends on the plan, the diagnosis code, and whether the prescription is written for diabetes or weight loss.
Insurance usually covers Ozempic and Mounjaro for type 2 diabetes more readily than for weight loss. Manufacturer savings programs can lower copays for commercially insured patients, and Medicare Part D rules have changed how much some enrollees pay.
When people compare tirzepatide vs ozempic cost, the answer often comes down to formulary placement rather than the sticker price. A fair tirzepatide vs ozempic price comparison should include copays, savings cards, and any required prior authorization.
Key conclusion: Without insurance, Mounjaro and Ozempic both cost roughly $1,000 or more per month in the United States.
Newer Options and Ongoing Research
Researchers continue to study next-generation compounds, including triple agonists that target GIP, GLP-1, and glucagon receptors. Early reports sometimes compare reta vs mounjaro dosage schedules, but retatrutide remains investigational and is not FDA-approved.
Oral semaglutide is available for type 2 diabetes, and additional oral and combination products are in late-stage trials. The treatment landscape is changing quickly, so current options may look different within a few years.
Talking With Your Prescriber
Choosing between Mounjaro and Ozempic is a medical decision, not a simple ranking. Insurance coverage, A1C goals, weight-loss goals, side-effect tolerance, and drug supply all shape the choice.
Bring your questions to a licensed healthcare professional. They can review your history, explain the risks, and adjust the dose gradually to limit side effects.
Frequently Asked Questions
What is the difference between tirzepatide and semaglutide?
Tirzepatide (Mounjaro, Zepbound) activates both GIP and GLP-1 receptors, while semaglutide (Ozempic, Wegovy) activates only GLP-1. That extra GIP activity is linked to greater average A1C reductions and weight loss in clinical trials. Both are given as once-weekly injections.
Is Mounjaro or Ozempic better for weight loss?
Trial data suggests tirzepatide produces greater average weight loss than semaglutide, but no head-to-head trial has compared them at their weight-loss doses. Mounjaro itself is approved for type 2 diabetes, not weight loss; Zepbound is the tirzepatide brand approved for that purpose. Ozempic is also not approved for weight loss, while Wegovy is.
How much do Mounjaro and Ozempic cost without insurance?
List prices for both medications are roughly $1,000 or more per month in the United States before insurance or savings programs. Manufacturer copay cards can lower costs substantially for people with commercial insurance. Coverage for weight loss is often more restrictive than coverage for type 2 diabetes.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.